Send to

Choose Destination
Arch Bronconeumol. 2013 Feb;49(2):79-81. doi: 10.1016/j.arbres.2012.04.003. Epub 2012 May 22.

Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.

[Article in English, Spanish]

Author information

Servicio de Oncología Médica, Hospital Universitario Arnau de Vilanova, Lleida, España.


It has been suggested that human papillomavirus (HPV) could participate in the development of non-small-cell lung cancer (NSCLC). A higher HPV infection rate has been reported in the NSCLC samples from Asian non-smoker patients, with adenocarcinomas or responders to EGFR tyrosine kinase inhibitors (EGFR-TKI). We explored a potential relationship between EGFR mutation, response to EGFR-TKI and HPV infection in Western NSCLC patients. We retrospectively analyzed 40 NSCLC samples and the impact of age, gender, histology, tobacco habit and sample type. HPV infection rate was 2.5% and it was not statistically modified by any analyzed variable, although the limited sample size did not provide definitive conclusions. The rate of HPV infection in NSCLC should be studied in patients with EGFR mutations or a tendency towards presenting them.

[Indexed for MEDLINE]
Free full text

MeSH terms, Substances

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center